Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
Scotiabank Sticks to Their Buy Rating for Tempest Therapeutics (TPST)
HC Wainwright & Co. Reiterates Buy on Tempest Therapeutics, Maintains $47 Price Target
Tempest Therapeutics Analyst Ratings
Buy Rating Affirmed for Tempest Therapeutics Amid Positive Developments and Strategic Roche Collaboration
Stocks alert: Tempest Therapeutics falls more than 11% as it reaches an agreement with Roche to advance liver cancer drug research.
Gelonghui October 10th | Drug developer Tempest Therapeutics (TPST.US) surged nearly 18% in early trading, but has since given back all gains and dropped over 11%, trading at $1.20. On the news front, Tempest Therapeutics will conduct late-stage research on its experimental drug amezalpat in combination with Swiss pharmaceutical company Roche's Tecentriq and bevacizumab monoclonal antibody for the treatment of metastatic liver cell carcinoma. Under the agreement, Roche will supply Tecentriq globally, and Tempest will support.